Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

May 31, 2007

Conditions
Prostatic Neoplasms
Interventions
BIOLOGICAL

TroVax

11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.

DRUG

GM-CSF

168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).

Trial Locations (1)

77030

The Methodist Hospital Research Institute, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oxford BioMedica

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER